Product

Increlex^® (mecasermin [rDNA origin] injection)

Increlex^® (mecasermin [rDNA origin] injection) is approved in the United States for the long-term treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone.

For full prescribing information, visit www.increlex.com.